No Data
No Data
TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial
TuHURA Biosciences and Kineta Present Updated Results From Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual...
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?
Press Release: TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
Express News | Tuhura Biosciences, Inc. Appoints DR. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
Press Release: TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
傑kit : Is it good or bad.
Trytosaveabit OP 傑kit : The data is good
傑kit Trytosaveabit OP : Thank you.